Swiss National Bank Grows Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Swiss National Bank lifted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,600 shares of the company’s stock after buying an additional 1,400 shares during the quarter. Swiss National Bank owned approximately 0.20% of TransMedics Group worth $4,090,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the period. State of Michigan Retirement System acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $6,734,000. Public Sector Pension Investment Board purchased a new stake in TransMedics Group during the 3rd quarter worth approximately $11,079,000. Raymond James Financial Inc. acquired a new stake in TransMedics Group during the 4th quarter worth approximately $3,845,000. Finally, Baillie Gifford & Co. lifted its holdings in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after buying an additional 34,947 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $70.79 on Wednesday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of 75.31 and a beta of 2.12. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a 50 day moving average price of $68.43 and a 200 day moving average price of $89.16.

Analyst Ratings Changes

A number of analysts have recently weighed in on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Oppenheimer reissued an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.